826 related articles for article (PubMed ID: 9247787)
1. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
Kotaki M; Uday K; Henriquez M; Blum S; Dave M
Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
[No Abstract] [Full Text] [Related]
2. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D
Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin.
Markowitz GS; Kahn GA; Feingold RE; Coco M; Lynn RI
Clin Nephrol; 1997 Jul; 48(1):34-40. PubMed ID: 9247776
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin.
Wingard RL; Parker RA; Ismail N; Hakim RM
Am J Kidney Dis; 1995 Mar; 25(3):433-9. PubMed ID: 7872321
[TBL] [Abstract][Full Text] [Related]
5. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
[TBL] [Abstract][Full Text] [Related]
7. Iron management during recombinant human erythropoietin therapy.
Van Wyck DB
Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):9-13. PubMed ID: 2757026
[TBL] [Abstract][Full Text] [Related]
8. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
9. Human recombinant erythropoietin (rHuEPO) in the treatment of anemia in patients with chronic renal failure (CRF): experience with a group of patients on chronic haemodialysis treatment.
Ramírez B; Flores A; Pérez F; Córdoba C; García L; Vázquez G
Transplant Proc; 1991 Apr; 23(2):1833-4. PubMed ID: 2053170
[No Abstract] [Full Text] [Related]
10. A comprehensive vision for intravenous iron therapy.
Coyne DW
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
[TBL] [Abstract][Full Text] [Related]
11. Effect of recombinant human erythropoietin on iron balance in maintenance hemodialysis: theoretical considerations, clinical experience and consequences.
Grützmacher P; Tsobanelis T; Roth P; Werner E; Vlachojannis J; Kaltwasser J; Kurz P; Scheuermann EH; Schoeppe W
Clin Nephrol; 1992; 38 Suppl 1():S92-7. PubMed ID: 1295714
[TBL] [Abstract][Full Text] [Related]
12. [Influence of iron metabolism on the efficacy of r-HuEPO (recombinant human erythropoietin) treatment of anemia in children on hemodialysis].
Pela I; Lavoratti GC; Materassi M; Burgio G; Bartolozzi G
Pediatr Med Chir; 1991; 13(5):475-7. PubMed ID: 1788107
[TBL] [Abstract][Full Text] [Related]
13. Adjusting i.v. iron and EPO doses in patients on hemodialysis prior to continuing surgery: can we protect our patients education from iron-deficiency anemia?
Deaver K; Bennington L
Nephrol Nurs J; 2006; 33(4):430-7; quiz 438. PubMed ID: 17002001
[TBL] [Abstract][Full Text] [Related]
14. Intravenous iron administration during the maintenance period in erythropoietin-treated hemodialysis patients: a simple and effective method.
Nurnuansuwan S; Leelahavanichkul A; Pansin P; Eiam-Ong S
J Med Assoc Thai; 2005 Sep; 88 Suppl 4():S184-8. PubMed ID: 16623026
[TBL] [Abstract][Full Text] [Related]
15. Maintaining higher TSATs and other iron indices is beneficial in management of anemic hemodialysis patients.
Besarab A; Dalton CL
Nephrol Nurs J; 2001 Aug; 28(4):429-34. PubMed ID: 12143465
[TBL] [Abstract][Full Text] [Related]
16. [Correction of anemia in hemodialysis, effect of intravenous iron without erythropoietin].
Alvo M; Elgueta L; Aragón H; Cotera A
Rev Med Chil; 2002 Aug; 130(8):865-8. PubMed ID: 12360794
[TBL] [Abstract][Full Text] [Related]
17. Iron balance following recombinant human erythropoietin therapy for anemia associated with chronic renal failure.
Hotta T; Ogawa H; Saito A; Ito A
Int J Hematol; 1991 Jun; 54(3):195-200. PubMed ID: 1747454
[TBL] [Abstract][Full Text] [Related]
18. Intravenous iron, inflammation, and oxidative stress: is iron a friend or an enemy of uremic patients?
Garneata L
J Ren Nutr; 2008 Jan; 18(1):40-5. PubMed ID: 18089442
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of IV iron compared to oral iron for increment of haemoglobin level in anemic chronic kidney disease patients on erythropoietin therapy.
Adhikary L; Acharya S
JNMA J Nepal Med Assoc; 2011; 51(183):133-6. PubMed ID: 22922860
[TBL] [Abstract][Full Text] [Related]
20. A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex-150 in ESRD patients receiving EPOGEN.
Johnson CA; Rosowski E; Zimmerman SW
Adv Perit Dial; 1992; 8():444-7. PubMed ID: 1361844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
